Paclitaxel and cisplatin as salvage treatment in patients with non-seminomatous germ cell tumour who failed to achieve a complete remission on induction chemotherapy

Clinical Oncology

Volumn 10, Issue 5, 1998, Pages 297-300

  Tjulandin, S A ^a,b   Titov, D A ^a   Breder, V V ^a   Sidorova, N J ^a   Popov, A J ^a   Kupchan, D Z ^a   Garin, A M ^a  

^a N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^b INSTITUTE OF PHARMACOLOGY   (Russian Federation)

Author keywords

Cisplatin; Germ cell tumours; Nonseminoma; Paclitaxel; Salvage chemotherapy

Indexed keywords

CISPLATIN; CREATININE; PACLITAXEL; PLATINUM DERIVATIVE; TUMOR MARKER;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DEATH; DRUG EFFICACY; DRUG INFUSION; FOLLOW UP; GERM CELL TUMOR; HUMAN; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

EID: 0031771219     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0936-6555(98)80080-0     Document Type: Article

References (7)

1. Einhorn LH. Treatment of testicular cancer: a new and improved model. J Clin Oncol 1990;8:1777-81.
2. Saxmann S. Salvage therapy in recurrent testicular cancer. Semin Oncol 1992;19:143-7.
3. Droz JP, Culine S, Biron P, et al. High-dose chemotherapy in germ-cell tumours. Ann Oncol 1996;7:997-1003.
4. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med 1995;332:1004-14.
5. Motzer RJ, Bajorin DF, Schwartz LH, et al. Phase II trial of paclitaxel shows antitumour reactivity in patients with previously treated germ cell tumours. J Clin Oncol 1994;12:2277-83.
6. Bokemeyer C, Beyer J, Metzner B, et al. Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol 1996;7:31-4.
7. Bokemeyer C, Schmoll HJ, Natt F, et al. Preliminary results of a phase I/II trial of paclitaxel in patients with relapsed or cisplatin-refractory disease. J Cancer Res Clin Oncol 1994;120:754-7.